TOP10 reimbursement value in Poland - September 2023

?? Updated September 2023 #DGL bulletin data

?? In September 2023, the cumulative #reimbursement amount stands at almost PLN 13.6 billion, which is 2 billion more than in the same period of the previous year.

??For the whole market, #Jardiance made it to the TOP10, jumping to 10th place on the list, with PLN 130 million cumulative reimbursement amount in the current year. ?

??For the #drug programmes, in the top 3 #Kaftrio switched places with #Spinraza and moved up to the 3rd position, with PLN 232 million cumulative reimbursement amount in the current year and a year-over-year change in the reimbursement amount of 305%.

??For the #outpatient list, #Forxiga moved up two places to the 3rd position, with PLN 121 million cumulative reimbursement amount in the current year and a year-over-year change in the reimbursement amount of 270%.

What's interesting, data for the medical devices market show that brands from TOP10 have over 84% of the market share.

More data in our IDA TOP10 report: https://app.powerbi.com/view?r=eyJrIjoiZGI3MDlkYWEtZDhmZi00MmIxLTlkNDctZTk3NjgyZWQyMjUyIiwidCI6IjFhYjJiNGUwLWE4ZmUtNGQ3OS1hY2Q1LTk2NzhlMThiN2IxOSIsImMiOjl9&embedImagePlaceholder=true

#healthcare #drugs #medical #ochronazdrowia #opiekazdrowotna #medycyna #medicine #hta #refundacja #programylekowe #oncology #drugprogrammes #MZ #NFZ #htaconsulting #PowerBi #analysis #pharmacy #pharma #dataanalysis #foodstuffs #IDA #leki #data #terapia #change